Cosmo Pharmaceuticals N.V. Sustainability Profile
Cosmo Pharmaceuticals N.V., a leading biopharmaceutical company headquartered in Ireland (IE), focuses on developing innovative treatments for gastrointestinal diseases and other specialised areas. Founded in 1997, Cosmo has established a strong presence in Europe and the United States, with significant operational activities in these key markets. The company is renowned for its unique drug delivery technologies, particularly in the field of endoscopy and gastrointestinal health. Its flagship products, including the advanced bowel preparation agent and proprietary drug formulations, set Cosmo apart in the competitive pharmaceutical landscape. With a commitment to research and development, Cosmo Pharmaceuticals has achieved notable milestones, positioning itself as a trusted name in the biopharmaceutical industry.
DitchCarbon Score
How does Cosmo Pharmaceuticals N.V.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Cosmo Pharmaceuticals N.V.'s score of 28 is lower than 53% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Cosmo Pharmaceuticals N.V.'s reported carbon emissions
Cosmo Pharmaceuticals N.V., headquartered in Ireland (IE), currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures. Consequently, there are no recorded Scope 1, 2, or 3 emissions to detail. Additionally, the company has not established any documented reduction targets or climate pledges, which limits the available information on their climate commitments. As a result, Cosmo Pharmaceuticals N.V. appears to be in the early stages of addressing carbon emissions and climate action within the pharmaceutical industry. Without specific data or targets, it is challenging to assess their environmental impact or commitment to sustainability initiatives.
How Carbon Intensive is Cosmo Pharmaceuticals N.V.'s Industry?
How Carbon Intensive is Cosmo Pharmaceuticals N.V.'s Location?
Cosmo Pharmaceuticals N.V.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Cosmo Pharmaceuticals N.V. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
